Vulvovaginal Atrophy
Conditions
Keywords
Vulvovaginal Dryness
Brief summary
The aim of the study is to gain further experience with regard to the performance of the medical device WO2085 Moisturising Cream for breast cancer patients undergoing chemotherapy or treatment with anti-oestrogens / aromatase inhibitors
Detailed description
The goal of this application study was to answer the question as to whether the application of WO2085 Moisturising Cream for breast cancer patients undergoing chemotherapy or treatment with anti-oestrogens / aromatase inhibitors can result in an improvement in the subjective symptoms and objective diagnoses of vulvovaginal dryness while also ensuring good tolerability.
Interventions
Week 1: 2.5 g of the investigational product WO2085 Moisturising Cream will be applied intravaginally, once daily in the evening. In addition 0.5 g (1 fingertip unit) may be applied to the outer genital area as needed (also several times per day). Week 2-4: The frequency may be reduced by the patient as needed. In addition 0.5 g (1 fingertip unit) may be applied to the outer genital area as needed (also several times per day).
Sponsors
Dr. Dimitrios Chatsiproios
Dr. med. Klaus König
SAM®, Statistische Analysen und Monitoring GmbH
Dr. August Wolff GmbH & Co. KG Arzneimittel
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Women with breast cancer undergoing chemotherapy OR therapy with aromatase inhibitors or anti-oestrogens (either at present or up to 3 months after ending treatment) AND with symptoms of vulvovaginal dryness since the start of tumour treatment * Written declaration of consent for the voluntary participation in the study is present
Exclusion criteria
* Women who suffered symptoms of vulvovaginal dryness prior to the start of tumour treatment * Patients undergoing radiation therapy * Patients with other tumours * A current vaginal infection * Medical conditions related to the vulva or vagina * Current additional therapy of vulvovaginal dryness or vulvovaginal atrophy * Women who are not able to participate properly in this study * Current alcohol and/or drug abuse * Pregnant or lactating women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from Baseline of subjective vulvovaginal atrophy symptoms (e.g. feeling of dryness, itching) | Baseline, after 4 weeks | Each symptom is rated according to severity on a scale from 0 to 4 (0=not present, 1=hardly pronounced, 2=moderately pronounced, 3=quite pronounced, 4=very pronounced) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from Baseline of objective vulvovaginal atrophy symptoms (e.g. thinning of the vaginal epithelium, redness) | 4 weeks | Each symptom is rated according to severity on a scale from 0 to 4 (0=not present, 1=hardly pronounced, 2=moderately pronounced, 3=quite pronounced, 4=very pronounced) |
| Global judgement of efficacy | 4 weeks | The global judgement of efficacy will be assessed by the investigator and the patient according to the following scale: 1=very good to 6=unsatisfactory. |
| Global judgement of tolerability | 4 weeks | The global judgement of tolerability will be assessed by the investigator and the patient according to the following scale: 1=very good to 6=unsatisfactory. |
| Adverse Events | after 4 weeks | Adverse events will be documented on Visit after 4 weeks (and in the patient diary, if applicable). |
Countries
Germany
Outcome results
None listed